A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Mascarenhas, John; E. Kosiorek, Heidi; T. Prchal, Josef; Rambaldi, Alessandro; Berenzon, Dmitriy; Yacoub, Abdulraheem; N. Harrison, Claire; Frances McMullin, Mary; M. Vannucchi, Alessandro; Ewing, Joanne; L. O'Connell, Casey; Kiladjian, Jean-Jacques; J. Mead, Adam; F. Winton, Elliott; S. Leibowitz, David; De Stefano, Valerio; O. Arcasoy, Murat; M. Kessler, Craig; Catchatourian, Rosalind; Rondelli, Damiano; T. Silver, Richard; Bacigalupo, Andrea; Nagler, Arnon; Kremyanskaya, Marina; F. Levine, Max; E. Arango Ossa, Juan; McGovern, Erin; Sandy, Lonette; E. Salama, Mohamad; Najfeld, Vesna; Tripodi, Joseph; Farnoud, Noushin; V. Penson, Alexander; Singer Weinberg, Rona; Price, Leah; D. Goldberg, Judith; Barbui, Tiziano; Marchioli, Roberto; Tognoni, Gianni; K. Rampal, Raajit; A. Mesa, Ruben; C. Dueck, Amylou; Hoffman, Ronald

doi:10.1182/blood.2021012743

Public

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Published in Blood • Jan 10, 2022

Authors:

John Mascarenhas

Heidi E. Kosiorek

Josef T. Prchal

Abstract

The goal of therapy for patients with essential thrombocythemia (ET) and polycythemia vera (PV) is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) and interferon-α (IFN-α) are the most frequently used cytoreductive options for patients with ET and PV at high risk for vascul...

Subject

Medicine

Essential thrombocythemia

Polycythemia vera

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!